Senate slaps Medicare on anemia drug coverage in Amgen win

Share this article:

Spurred by a strong lobbying effort by Amgen, the Senate on Tuesday called on the Centers for Medicare and Medicaid Services to reconsider its decision to restrict coverage of Epogen and Aranesp.

CMS's July move on the Amgen anemia drugs prompted major layoffs at the Thousand Oaks, CA company.

As the resolution, sponsored by Sens. Arlen Specter (R-PA) and Frank Lautenberg (D-NJ), was non-binding, it is unclear how much pressure it will place on CMS to reverse its decision.
Amgen also has the American Society of Clinical Oncology on its side. The society recently said the restriction interferes with physicians' ability to care for patients suffering from anemia.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.